STAR

Strides Pharma Science Ltd.

NSE: STAR

BSE: 532531

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,126.80+0.4 (+0.04%)

3 Jul, 3:30 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

76.8 / 100

Value Score

47.1 / 100

Price Momentum Score

87.5 / 100

QVM Score

89.3 / 100

Key Metrics

Market Cap

10382.40

P/E (TTM)

18.67

P/B

3.34

P/S (TTM)

2.14

EV/EBITDA

12.68

CAPE (5Y)

379.58

ROE (TTM)

19.66

ROCE (TTM)

15.42

ROA (TTM)

8.57

Avg 3Y ROE

108.99

Earnings 3Y CAGR

11.06

Sales 3Y CAGR

9.62

Sales 5Y CAGR

7.94

Debt/Equity

0.57

Consensus TP

1410.00

Strong Buy %

Promoter Holding

27.91

Pledged %

27.27

Stock Analysis

Fundamental analysis overview of Strides Pharma Science Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 18.67 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -38.3%

What is P/E Ratio?

Median: 30.26

Value 18.67

-215.443183

Strong price momentum

Price Momentum score of 87.5 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

87.5 / 100

Moderate operating margin but improving trend

The company reported moderate operating margin of 14.88% for 12-month ended 31 Mar 2026 but operating margin improved by 150 bps from 1 year ago

What is Operating profit margin?

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 36.98% for 12-month ended 31 Mar 2026 and the growth was 28.86 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.57 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.17 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 3 financial years

What is Dividend streak?

Negative

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -0.16% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 6.43% for 12-month ended 31 Mar 2026 and the growth was 4.81 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 6.43

-82.35114662

Low dividend yield

The company has a low dividend yield of 0.36%

What is Dividend yield?

Neutral

High ROE but declining trend

The company reported strong ROE of 19.66% for 12-month ended 31 Mar 2026 but ROE declined by -13399 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 65.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

65.9 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Strides Pharma Science Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Strides Pharma Science Ltd. Shareholding Pattern

Quarterly breakdown of Strides Pharma Science Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	31.27	29.71	29.69	29.69	29.67	29.62	29.60	29.60	30.60	30.37	31.07	30.89	28.27	28.07	27.78	27.39	25.88	25.86	25.84	26.82	28.30	28.30	27.86	27.86	27.91
Indian Promoter	31.27	29.71	29.50	29.48	29.40	29.35	29.33	29.33	30.33	30.10	30.81	30.63	28.06	27.86	27.78	27.39	25.88	25.86	25.84	26.82	28.30	28.30	27.86	27.86	27.91
Foreign Promoter	-	-	0.20	0.21	0.27	0.27	0.27	0.27	0.27	0.27	0.27	0.27	0.21	0.21	-	-	-	-	-	-	-	-	-	-	-
Institutions	47.68	46.18	42.24	41.81	40.90	40.42	45.40	40.93	38.48	37.84	36.90	37.83	37.14	36.72	37.16	38.86	42.62	45.28	48.33	45.41	42.05	41.33	41.50	42.55	43.14
Mutual Funds / UTI	15.08	15.64	15.12	15.47	14.81	13.22	14.21	14.84	12.39	9.81	8.32	11.65	11.14	13.86	13.67	13.09	10.57	10.50	10.80	10.86	8.89	8.82	8.48	8.59	8.56
FI/Bank/Insurance	3.78	3.73	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	5.27	5.27	5.21	4.55	4.55	4.47	5.78	6.17	5.87	4.31	3.03	2.87	2.95	3.06	4.55
Govt	-	-	-	-	-	-	-	-	-	-	-	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
FII	28.80	26.78	26.96	25.16	24.82	25.80	24.96	19.85	19.66	21.21	21.38	18.93	18.80	16.67	17.21	19.45	24.57	26.71	30.08	28.48	28.32	28.02	28.51	29.52	28.68
Other Institutions	0.02	0.02	0.15	1.17	1.25	1.38	6.20	6.22	6.42	6.80	1.93	1.96	1.97	1.63	1.72	1.84	1.69	1.88	1.57	1.75	1.80	1.61	1.55	1.37	1.33
Non-Institution	21.05	24.11	28.07	28.50	29.42	29.96	25.00	29.47	30.92	31.79	32.03	31.28	34.59	35.21	35.06	33.75	31.50	28.87	25.83	27.77	29.65	30.37	30.64	29.59	28.95
Bodies Corporate	-	-	-	-	-	-	-	-	-	-	5.58	4.83	4.98	5.55	7.45	6.73	5.97	3.73	3.15	2.82	3.82	3.87	3.83	3.97	3.97
Others (incl. Retail) No. of shareholders	21.05 73,064	24.11 84,411	28.07 79,381	28.50 71,368	29.42 73,898	29.96 96,812	25.00 1,06,759	29.47 1,25,390	30.92 1,33,016	31.79 1,34,542	26.45 1,29,843	26.45 1,23,181	29.61 1,20,180	29.66 1,11,969	27.61 1,00,865	27.02 90,409	25.53 83,968	25.14 90,977	22.68 94,940	24.95 1,12,931	25.83 94,020	26.50 91,875	26.81 90,210	25.62 84,686	24.98 85,544

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Microcap 250	0.89%	13 / 250
2	Nifty Total Market	0.04%	364 / 749

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Strides Pharma Science Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
PRONOMZ VENTURES LLP Promoter	March-2022	Market Purchase (Acquisition) 25th Mar 2022	18.80 %	₹ 350.68	45.45 k	₹ 1.59 cr
PRONOMZ VENTURES LLP Promoter	March-2022	Market Purchase (Acquisition) 24th Mar 2022	18.74 %	₹ 330.08	53.20 k	₹ 1.76 cr
AGRAGANYA PRIVATE TRUST Promoter Group	March-2022	Market Purchase (Acquisition) 17th Mar 2022	0.00 %	₹ 323.42	3.00 lac	₹ 9.70 cr
PRONOMZ VENTURES LLP Promoter	March-2022	Market Purchase (Acquisition) 15th Mar 2022	18.42 %	₹ 320.79	2.91 lac	₹ 9.34 cr
PRONOMZ VENTURES LLP Promoter	March-2022	Market Purchase (Acquisition) 4th Mar 2022	18.36 %	₹ 318.02	52.00 k	₹ 1.65 cr
Arun Kumar Promoter & Director	February-2022	Market Purchase (Acquisition) 28th Feb 2022	1.54 %	₹ 321.59	1.55 lac	₹ 4.99 cr
Karuna Business Solutions LLP Promoter Group	February-2022	Market Purchase (Acquisition) 28th Feb 2022	1.36 %	₹ 327.31	1.55 k	₹ 5.07 lac
Amit Kumar Himmatsinghka Designated Person	September-2021	Market Sale (Disposal) 28th Sep 2021	0.00 %	₹ 639.76	2.60 k	₹ 16.63 lac
Sandeep Baid Designated Person	September-2021	Market Sale (Disposal) 24th Sep 2021	0.00 %	₹ 628.85	4.00 k	₹ 25.15 lac
Aravinda R Designated Person	September-2021	Market Sale (Disposal) 22nd Sep 2021	0.00 %	₹ 602.30	2.50 k	₹ 15.06 lac

Corporate Actions

History of Strides Pharma Science Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 4/share
Record date: 22nd Jul 2025Ex-date: 22nd Jul 2025
Announced on: 22nd May 2025
Others
Ex-date: 6th Dec 2024Announced on: 25th Sep 2023
"As part of Demerger each shareholder entitled to receive 1 common share of OneSource Specialty Pharma Ltd formerly known as Stelis Biopharma Limited for every…
Dividend₹ 2.50/share
Record date: 9th Sep 2024Ex-date: 9th Sep 2024
Announced on: 22nd May 2024
Dividend₹ 1.50/share
Record date: 4th Aug 2023Ex-date: 4th Aug 2023
Announced on: 25th May 2023
Dividend₹ 2.50/share
Record date: 6th Aug 2021Ex-date: 5th Aug 2021
Announced on: 27th May 2021

Company Profile

Overview of Strides Pharma Science Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa,...

Key personnel

Mr. Vikesh Kumar

Group Chief Financial Officer

Ms. Manjula Ramamurthy

Compliance Officer, Company Secretary

Mr. Umesh Kale

Chief of Quality Services

Mr. Arun Kumar PillaiD

Non-Executive Chairman of the Board

Mr. Badree KomandurD

Group Chief Executive Officer, Managing Director, Executive Director

Mr. Venkata Seetharama Raju (Ram) PakalapatiD

Executive Director

Mr. Aditya Arun KumarD

Non-Executive Director

Ms. Mukta AroraD

Additional Independent Director

View all

Incorporated on

28 Jun 1990

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

03 Feb 2000

Free Float

6,27,46,395

Website

https://www.strides.com/

Phone no.

+912227892924

Address

Strides House, Bilekahalli, Bannerghatta Road, BANGALORE, 560076, India

Frequently Asked Questions

What is the current share price of Strides Pharma Science Ltd.?

The current share price of Strides Pharma Science Ltd. is ₹ 1,126.80 as of 3 Jul 2026.

What is the market capitalisation of Strides Pharma Science Ltd.?

The market capitalisation of Strides Pharma Science Ltd. stands at ₹ 10,382.40 Cr.

What is the PE ratio of Strides Pharma Science Ltd.?

The Price-to-Earnings (PE) ratio of Strides Pharma Science Ltd. is 18.67 as of the latest trailing twelve months data.

What is the ROE and ROCE of Strides Pharma Science Ltd.?

Strides Pharma Science Ltd. has a Return on Equity (ROE) of 19.66% and a Return on Capital Employed (ROCE) of 15.42% as per the latest financial reports.

What is the 52-week high and low of Strides Pharma Science Ltd.?

The 52-week high of Strides Pharma Science Ltd. is - and the 52-week low is -.

What is the dividend yield of Strides Pharma Science Ltd.?

The dividend yield of Strides Pharma Science Ltd. is 0.36% based on the current market price.

What is the FII and DII holding in Strides Pharma Science Ltd.?

Foreign Institutional Investors (FII) hold 28.68%, Domestic Institutional Investors (DII) hold 13.11% and retail/public investors hold 24.98% of Strides Pharma Science Ltd. shares.

What sector does Strides Pharma Science Ltd. belong to?

Strides Pharma Science Ltd. operates in the Healthcare sector.

What is the beta of Strides Pharma Science Ltd.?

The beta of Strides Pharma Science Ltd. is 0.61, indicating its price volatility relative to the broader market. Over the past 1 year, Strides Pharma Science Ltd. has delivered an absolute return of 35.28%.

What is the RSI of Strides Pharma Science Ltd.?

The 14-day Relative Strength Index (RSI) of Strides Pharma Science Ltd. is 57.91, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Strides Pharma Science Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Strides Pharma Science Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Corporate Actions

Company Profile

Holdings and Presence